TIAKI THERAPEUTICS

At Tiaki, we are passionate about the potential of our approach and our first focus is identifying treatments for neurodegenerative diseases... Our approach targeting microglia represents a promising new therapeutic strategy. Distinct from historical drug development in CNS disease, Tiaki's approach is designed to target the neuroinflammatory state that drives cognitive decline and thereby restore normal function to the underlying dysregulated pathways involving microglia... Tiaki has identified a transcriptomic signature of neuroinflammation in dementia patients that can be used to nominate targets for drug development. These targets from patients have been validated in our proprietary discovery engine that models the conserved biology of neuroinflammation. Our differentiated approach leverages this conserved biology to drive the development of novel therapeutic targets and biomarkers in patients with multiple neurodegenerative diseases.

Also known as: Tiaki, Tiaki Therapeutics Inc.

Primary location: Cambridge United States